布拉氏酵母菌散联合匹维溴铵治疗感染后肠易激综合征疗效的观察

Observation on the Effect of Bladders Yeast Powder Combined with Pinaverium Bromide in the Treatment of Irritable Bowel Syndrome after Infection

目的:探究布拉氏酵母菌散治疗感染后肠易激综合征的疗效。方法:选取120例于我院消化内科就诊的感染后肠易激综合征患者,随机分为对照组和实验组各60例,对照组予以匹维溴铵,实验组予以布拉氏酵母菌散+匹维溴铵,两组均根据患者大便性状联合或不联合蒙脱石散(腹泻)/聚乙二醇4000散(大便干结),比较两组的总治疗有效率和BSS积分。结果:实验组总有效率为91.67%,显著高于对照组的78.33%,治疗后两组的BSS总分及各项目积分均显著低于治疗前,除腹胀程度外,实验组治疗后的积分也都显著低于对照组。结论:布拉氏酵母菌可以通过多重作用机制保护肠黏膜,对抗病原菌,恢复肠道微环境,可有效降低患者BSS积分,并且安全、无明显毒副作用,今后其在肠应激综合征、溃疡性结肠炎等炎性肠病的应用前景十分广阔。

Objective:To explore the efficacy of Saccharomyces boulardii powder in the treatment of irritable bowel syndrome after infection.Methods:120 patients with irritable bowel syndrome (IBS) were randomly divided into two groups:control group and experimental group,60 cases in each group,control group and experimental group.The control group was given pivium bromide,and the experimental group was given Saccharomyces boulardii powder + pivium bromide.The two groups were combined or not combined with montmorillonite powder (diarrhea) / polyethylene glycol 4000 powder (dry stool) according to the characteristics of patients’ stool.The total treatment effect of the two groups was compared Rate and BSS integral.Re sults:The total effective rate of the experimental group was 91.67%,which was significantly higher than 78.33% of the control group.After treatment,the total score of BSS and the score of each item in the two groups were significantly lower than those before treatment.Except for the degree of abdominal distension,the score of the experimental group after treatment was also significantly lower than that of the control group.Conclusion:Saccharomyces boulardii can protect intestinal mucosa,resist pathogenic bacteria and restore intestinal microenvironment through multiple mechanisms.It can effectively reduce BSS score of patients,and it is safe and has no obvious toxic and side effects.In the future,s.boulardii has a broad application prospect in inflammatory bowel diseases such as intestinal stress syndrome and ulcerative colitis.